查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984173

分子腫瘤診斷市場：2026-2032年全球市場預測（按產品類型、技術、癌症類型、檢體類型、應用和最終用戶分類）

Molecular Oncology Diagnostics Market by Product Type, Technology, Cancer Type, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，分子腫瘤診斷市場價值將達到 22.3 億美元，到 2026 年將成長至 28.5 億美元，到 2032 年將達到 141.1 億美元，複合年成長率為 30.13%。

主要市場統計數據
基準年 2025 22.3億美元
預計年份：2026年 28.5億美元
預測年份 2032 141.1億美元
複合年成長率 (%) 30.13%

針對分子腫瘤診斷的簡明策略框架，重點在於相關人員在臨床整合方面所面臨的挑戰和創新重點。

分子腫瘤診斷領域正經歷著策略重組，其驅動力來自於技術的快速成熟、臨床實踐的演進以及醫療體系優先事項的轉變。重組的核心在於彌合基因組學見解與臨床應用之間的鴻溝，從而實現更早期的疾病檢測、更精準的治療方法選擇以及對疾病動態的持續監測。診斷創新不僅限於檢測靈敏度，還涵蓋工作流程整合、數據解讀以及將分子特徵轉化為臨床醫生可以放心使用的治療方案。

技術融合、監管調整和商業性合作如何從根本上改變臨床引入和產品差異化的路徑。

多項變革正在重塑分子腫瘤診斷在研究、臨床實踐和商業管道中的價值交付方式。首先，高通量定序技術與先進生物資訊學的融合提高了腫瘤譜分析的精細度，使臨床醫生能夠擺脫基於單一標誌物的決策模式，並利用複雜的基因組特徵來輔助治療方法的選擇和監測。其次，微創檢測正從概念驗證階段走向常規臨床應用，加速疾病的長期監測，並實現復發和抗藥性機制的早期發現。

針對 2025 年美國關稅調整，我們的營運和策略應對措施是重組我們的採購、製造地和採購風險管理。

美國近期推出的關稅措施以及針對2025年的貿易政策調整，正在為支持分子腫瘤診斷的全球供應鏈帶來明顯的摩擦。儀器製造、試劑配製和耗材生產所需的關鍵組件通常依賴海外採購，而關稅結構的變化推高了進口原料的成本，同時也促使供應商重組。這一趨勢迫使診斷試劑製造商和檢查室營運商重新評估供應商多元化、庫存策略和合約條款，以保障利潤率並避免檢測能力中斷。

透過對產品、技術、測試、應用、癌症類型、最終用戶和檢體類型進行多方面的細分，可以確定策略性產品設計和臨床實施路徑。

細分市場分析表明，產品差異化日益取決於儀器、試劑/試劑盒和軟體/服務之間的相互作用。具體而言，儀器支援檢查室工作流程，試劑/試劑盒確保檢測的特異性，而軟體/服務則提供解讀的廣度和監管可追溯性。技術選擇對臨床路徑有顯著影響。螢光雜合反應(FISH) 和免疫組織化學在標靶應用中仍然至關重要，微陣列繼續為特定的研究和轉化應用做出貢獻，而即時PCR提供快速且精準的分析。次世代定序(NGS) 因其廣度和深度而脫穎而出。在 NGS 中，標靶定序、全外顯EXOME定序和全基因測序各自提供不同的臨床和研究效用，而標靶定序本身又進一步分為綜合性 panel 和熱點聚焦 panel。這些 panel 分別針對廣譜、可操作的突變發現或精簡的、以臨床為導向的突變檢測進行了最佳化。

影響監管參與、商業化模式和跨國業務擴張的區域策略差異和實施重點。

區域趨勢表明，美洲、歐洲、中東和非洲以及亞太地區在優先事項和業務需求方面存在差異，這影響診斷開發人員和實驗室如何制定監管策略、夥伴關係模式和服務交付方式。在美洲，臨床和商業活動通常專注於將診斷整合到既定的腫瘤治療路徑中，並與尋求明確臨床效用證據的保險公司協商保險覆蓋範圍。該地區強調快速臨床檢驗和與治療藥物研發的密切合作，從而推動了診斷提供者和藥物開發商之間的合作模式。

診斷藥物創新者和檢測實驗室如何在競爭激烈的分子腫瘤學領域中脫穎而出，制定競爭定位和夥伴關係策略。

分子腫瘤診斷領域的競爭動態由成熟的儀器供應商、專業的檢測方法開發公司、檢查室網路以及新興的數位分析平台共同塑造。主要企業憑藉檢驗的分析性能、可重複的臨床級檢測方法以及符合監管和檢查室認證標準的完善品管系統脫穎而出。與製藥公司合作開發伴隨診斷仍然是獲得臨床意義的主要途徑，這種合作模式能夠產生共同的證據，並透過將診斷公司與治療創新路徑結合，推動產品進入臨床應用。

為產業領導者提供具有高影響力、可操作的策略行動，以加速臨床部署、保護業務營運並增強商業性價值提案。

產業領導者應優先採取一系列切實可行的步驟，將策略意圖轉化為可衡量的營運成果。首先，他們應投資可互通的數據平台和決策支援工具，以增強基因組分析結果的臨床效用，並減輕臨床醫生的認知負擔。這些平台應支援標準化報告，與電子健康記錄整合，並提供簡潔明了、可操作的解讀，供臨床醫生直接應用於治療決策。其次，他們應制定模組化的證據策略，將分析檢驗與真實世界績效數據結合，從而在滿足監管要求和支付方需求的同時，不斷完善臨床效用價值的論點。

採用透明嚴謹的調查方法，結合關鍵相關人員的訪談、二手資料的整合以及基於情境的分析檢驗。

支持這些研究結果的調查方法結合了證據整合、相關人員參與和嚴謹的分析檢驗，以確保其相關性和可靠性。主要研究包括對臨床腫瘤學家、實驗室經理、診斷試劑開發人員、採購經理和監管顧問進行結構化訪談，以了解第一線觀點對臨床工作流程、檢驗預期和採購決策的看法。次要研究則納入了同行評審的科學文獻、最新的臨床指南、監管出版物和運營實施案例研究，以闡明主要研究結果的背景並識別新興技術趨勢。

將分析嚴謹性、臨床整合和營運韌性連結起來，並整合策略重點，以最大限度地發揮臨床和商業性影響。

總之，分子腫瘤診斷處於技術潛力和臨床需求的交會點。要產生切實的影響，僅僅改進檢測方法遠遠不夠；我們需要一個整合的解決方案，將分析能力與臨床醫生的工作流程、循證策略、供應鏈的韌性以及支付方的期望相協調。那些採用互通資料平台、模組化證據產生方法並與藥物研發公司建立策略夥伴關係的機構，將更有能力將基因組學見解轉化為常規臨床決策。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 分子腫瘤診斷市場：依產品類型分類

  • 裝置
  • 試劑和試劑盒
  • 軟體服務

第9章 分子腫瘤診斷市場：依技術分類

  • 螢光原位雜合反應
  • 免疫組織化學
  • 微陣列
  • 次世代定序
    • 目標序列
      • 整合面板
      • 熱點面板
    • 全EXOME定序
    • 全基因組定序
  • 即時PCR

第10章 依癌症類型分類的分子腫瘤診斷市場

  • 乳癌
  • 結腸癌
  • 白血病
  • 肺癌
  • 攝護腺癌

第11章 依樣本類型分類的分子腫瘤檢體市場

  • 基於等離子體
  • 唾液/尿液
  • 組織起源
  • 全血

第12章 分子腫瘤診斷市場：依應用分類

  • 伴隨診斷
  • 早期檢測
  • 個人化醫療
  • 預後預測和監測
  • 出於研究目的

第13章 分子腫瘤診斷市場：依最終用戶分類

  • 診斷檢測實驗室
  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第14章 分子腫瘤診斷市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 分子腫瘤診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 分子腫瘤診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國分子腫瘤診斷市場

第18章：中國分子腫瘤診斷市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Bayer AG
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis NV
  • Biocept, Inc.
  • BIOMERIEUX SA
  • Danaher Corporation
  • DiaSorin Molecular LLC
  • Enzo Biochem, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • GenMark Saglik
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina Inc.
  • Leica Biosystems Nussloch GmbH
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories
  • OncoCyte Corporation
  • PathAI, Inc.
  • Personal Genome Diagnostics Inc.
  • QIAGEN NV
  • Siemens AG
  • Sysmex Asia Pacific Pte Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFE6

The Molecular Oncology Diagnostics Market was valued at USD 2.23 billion in 2025 and is projected to grow to USD 2.85 billion in 2026, with a CAGR of 30.13%, reaching USD 14.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.23 billion
Estimated Year [2026] USD 2.85 billion
Forecast Year [2032] USD 14.11 billion
CAGR (%) 30.13%

A concise strategic framing of the molecular oncology diagnostics domain highlighting clinical integration challenges and innovation priorities for stakeholders

The molecular oncology diagnostics landscape is undergoing a period of strategic realignment driven by rapid technological maturation, evolving clinical practice, and shifting health system imperatives. At its core, the field seeks to close gaps between genomic insight and clinical actionability, enabling earlier detection, more precise therapeutic selection, and continuous monitoring of disease dynamics. Diagnostic innovation is not limited to assay sensitivity; it spans workflow integration, data interpretation, and the translation of molecular signatures into treatment pathways that clinicians can deploy with confidence.

Clinicians, laboratory leaders, and industry stakeholders now face the dual challenge of validating complex assays while ensuring they integrate seamlessly into existing diagnostic and treatment workflows. Adoption depends on reproducible performance, regulatory clarity, and demonstrable utility across diverse patient populations. Meanwhile, payers and health systems increasingly demand evidence of clinical and economic value, prompting diagnostic developers to design studies and evidence packages that respond directly to these decision criteria.

As a result, leaders in molecular oncology diagnostics must balance innovation with pragmatic commercialization strategies. They must invest in robust analytical validation and clinical validation efforts, while also developing clear clinical use cases and data infrastructures that support interpretation and reporting. In this environment, high-quality, timely intelligence about technological trends, clinical adoption patterns, and stakeholder incentives becomes essential for shaping investment, collaboration, and market entry decisions.

How technological convergence, regulatory adaptation, and commercial alliances are fundamentally altering pathways for clinical adoption and product differentiation

Several transformative shifts are reshaping how molecular oncology diagnostics deliver value across research, clinical practice, and commercial channels. First, the convergence of high-throughput sequencing capabilities with advanced bioinformatics has expanded the granularity of tumor profiling, enabling clinicians to move beyond single-marker decisions toward composite genomic signatures that inform therapy selection and monitoring. Second, minimally invasive testing modalities have advanced from proof-of-concept to routine clinical utility, accelerating longitudinal disease monitoring and enabling earlier detection of relapse or resistance mechanisms.

Concurrently, regulatory and reimbursement pathways have become more dynamic, with agencies and payers signaling willingness to engage on evidence frameworks that accommodate innovative diagnostic modalities. This has encouraged more iterative evidence generation strategies that pair real-world data with prospective validation, fostering faster clinical adoption when utility is demonstrable. At the same time, integration of molecular diagnostics into oncology care is catalyzing new commercial partnerships between assay developers, diagnostics laboratories, and therapeutic companies, aligning diagnostic development timelines with drug development and label expansion strategies.

These shifts collectively demand that diagnostic providers focus on scalable laboratory operations, interoperable data platforms, and interpretive algorithms that deliver clinically meaningful, reproducible outputs. Strategic differentiation increasingly rests on end-to-end solutions that combine robust analytic performance with streamlined clinician-facing reports and decision-support tools. As the field evolves, organizations that master both the science and the operational pathways to clinical implementation will capture the greatest long-term value.

Operational and strategic responses to United States tariff adjustments in 2025 that are reshaping sourcing, manufacturing footprints, and procurement risk management

Recent tariff actions and trade policy adjustments in the United States for 2025 have introduced measurable friction into global supply chains that support molecular oncology diagnostics. Components critical to instrument manufacture, reagent formulation, and consumable production are often sourced internationally, and changes in tariff structures raise the cost of imported inputs while incentivizing supplier reconfiguration. This dynamic has prompted diagnostic manufacturers and laboratory operators to reassess supplier diversity, inventory strategies, and contract terms to protect margins and maintain uninterrupted testing capacity.

In response, many organizations have diversified their supplier base, sought local production partnerships, or initiated dual-sourcing strategies to reduce exposure to single-point supply risks. Procurement teams increasingly factor tariff volatility into total cost of ownership calculations, emphasizing end-to-end resilience and lead-time visibility. At the same time, manufacturers are evaluating the feasibility of regionalized manufacturing footprints and selective vertical integration for high-value components to mitigate exposure to trade-related shocks.

The policy-induced changes also influence commercial negotiations, with buyers and vendors renegotiating pricing and service commitments to reflect evolving input costs. For laboratories and health systems, the immediate priority is maintaining access to validated assays and preserving test continuity. For developers and instrument manufacturers, the strategic focus remains on balancing cost containment with the imperative to invest in innovation and quality control. Ultimately, resolving tariff-related disruption requires coordinated operational adjustments and forward-looking sourcing strategies that align with clinical demand and regulatory expectations.

How multi-dimensional segmentation across product, technology, test, application, cancer type, end user, and sample type determines strategic product design and clinical deployment pathways

Segmentation insight reveals that product differentiation is increasingly defined by the interplay between instruments, reagents and kits, and software and services, where instruments anchor laboratory workflows, reagents and kits enable assay specificity, and software and services deliver interpretive scale and regulatory traceability. Technology choices exert a profound influence on clinical pathways: fluorescence in situ hybridization and immunohistochemistry remain essential for targeted applications, microarray continues to serve select research and translational use cases, and real-time PCR provides rapid, focused analyses. Next generation sequencing stands out for breadth and depth; within NGS, targeted sequencing, whole exome sequencing, and whole genome sequencing offer distinct clinical and research utilities, and targeted sequencing itself differentiates into comprehensive panels and hotspot-focused panels, each optimized for either broad actionable variant discovery or streamlined, clinically focused mutation detection.

Test type segmentation shapes service design and clinical value propositions. Liquid biopsy enables minimally invasive longitudinal monitoring, multi-gene panel testing supports simultaneous interrogation of clinically relevant pathways, single gene testing delivers focused actionable results, and whole exome and whole genome approaches provide discovery-oriented breadth that can inform complex or refractory cases. Application-driven strategies must align companion diagnostics with therapeutic pathways, prioritize early detection modalities for population health impacts, and support personalized medicine through prognosis and monitoring tools while addressing research use needs.

Cancer type focus remains a critical lens for clinical relevance, with breast, colorectal, leukemia, lung, and prostate cancer each presenting distinct biomarker landscapes and care pathways that influence assay selection and validation requirements. End users - diagnostic laboratories, hospitals and clinics, pharmaceutical and biotech companies, and research institutes - have divergent operational constraints and purchasing drivers, which necessitates tailored product and service models. Finally, sample type considerations, spanning plasma-based assays, saliva and urine modalities, tissue-based testing, and whole blood analyses, determine pre-analytical workflows and influence analytic sensitivity and specificity. Taken together, these segmentation dimensions require cohesive strategies that link product design, clinical utility, and deployment environments to maximize clinical adoption and operational efficiency.

Regional strategic distinctions and execution priorities that influence regulatory engagement, commercialization models, and cross-border operational scaling

Regional dynamics reveal differentiated priorities and operational imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific, shaping how diagnostics developers and laboratories approach regulatory strategy, partnership models, and service delivery. In the Americas, clinical and commercial activities often center on integrating diagnostics into established oncology care pathways and negotiating coverage with payers that demand clear evidence of clinical utility. This region emphasizes rapid clinical validation and close alignment with therapeutic development, driving collaborative models between diagnostics providers and pharmaceutical developers.

In Europe, the Middle East & Africa, regulatory harmonization and variable reimbursement landscapes prompt stakeholders to design adaptable evidence generation strategies that can address diverse national requirements. Organizations operating across these markets prioritize modular data packages and centralized laboratory services while also engaging local clinical networks to validate utility in region-specific patient populations. The Asia-Pacific region features a mix of large, high-volume healthcare systems and rapidly developing molecular capabilities, encouraging investments in scalable testing platforms, local manufacturing partnerships, and digital reporting systems that support high-throughput workflows.

Transitioning across regions requires sensitivity to differing healthcare financing models, clinician practice patterns, and laboratory infrastructure. Successful market entrants adapt regulatory and commercial approaches to each region's institutional landscape, engage early with local clinical and payer stakeholders, and tailor go-to-market strategies that reflect regional diagnostic adoption curves and operational capacity. Coordinated regional strategies that leverage centralized data insights while accommodating local execution imperatives will be critical for sustained impact.

Competitive positioning and partnership strategies that enable diagnostic innovators and laboratories to differentiate in a crowded molecular oncology landscape

Competitive dynamics in molecular oncology diagnostics are shaped by a mix of established instrument providers, specialized assay developers, laboratory networks, and emerging digital interpretation platforms. Leading players distinguish themselves through validated analytical performance, reproducible clinical-grade assays, and robust quality management systems that satisfy regulatory bodies and laboratory accreditation standards. Collaboration with pharmaceutical developers on companion diagnostics continues to be a primary route to clinical relevance, positioning diagnostic companies alongside therapeutic innovation pathways and enabling joint evidence generation that supports simultaneous clinical adoption.

Smaller, agile firms frequently compete on niche innovations - for example, highly optimized targeted sequencing panels, proprietary sample stabilization chemistries, or interpretive algorithms that improve variant classification and reduce turnaround time. These firms often partner with larger laboratories or engage in licensing deals to scale reach and accelerate clinical deployment. At the same time, laboratory networks and reference testing providers expand their service portfolios by integrating advanced assays and investing in automation and bioinformatics to offer turn-key solutions to health systems and clinical trial sponsors.

Across the competitive landscape, differentiation increasingly relies on end-to-end capabilities that combine analytical excellence with clinician-facing reporting, payer-aligned evidence packages, and operational scalability. Alliances and strategic partnerships remain central to growth strategies, enabling companies to pair technical strengths with distribution channels, reimbursement expertise, and clinical advocacy that drive adoption.

High-impact and implementable strategic actions for industry leaders to accelerate clinical adoption, safeguard operations, and strengthen commercial value propositions

Industry leaders should prioritize a set of actionable moves that translate strategic intent into measurable operational outcomes. First, invest in interoperable data platforms and decision-support tools that enhance the clinical utility of genomic findings and reduce clinician cognitive load. These platforms should support standardized reporting, integrate with electronic health records, and provide concise, actionable interpretations that clinicians can apply directly to treatment decisions. Second, develop modular evidence strategies that combine analytical validation with real-world performance data to satisfy both regulatory requirements and payer demands while enabling iterative refinement of clinical utility claims.

Third, strengthen supply chain resilience by diversifying suppliers and exploring regional manufacturing partnerships for critical components and reagents, thereby reducing exposure to policy-driven cost disruptions. Fourth, pursue targeted partnerships with therapeutic developers to co-develop companion diagnostics, ensuring alignment between assay design and clinical trial endpoints. Fifth, tailor commercial models to end-user needs by offering flexible laboratory solutions, from centralized reference services to distributed testing models supported by robust quality assurance and training programs. Finally, embed health economics and outcomes research early in product development to articulate value to payers and providers, facilitating more rapid reimbursement discussions and clinical uptake.

By executing these initiatives in an integrated fashion, organizations can accelerate clinical adoption, protect margin, and create durable differentiation within the molecular oncology diagnostics ecosystem.

A transparent and rigorous research methodology combining primary stakeholder interviews, secondary literature synthesis, and scenario-based analytical validation

The research methodology underpinning these insights combines evidence synthesis, stakeholder engagement, and rigorous analytical vetting to ensure relevance and reliability. Primary engagement included structured interviews with clinical oncologists, laboratory directors, diagnostic developers, procurement leaders, and regulatory advisors to capture firsthand perspectives on clinical workflows, validation expectations, and purchasing drivers. Secondary analysis incorporated peer-reviewed scientific literature, clinical guideline updates, regulatory publications, and case studies of operational implementations to contextualize primary findings and identify emergent technological trends.

Analytic approaches emphasized cross-validation of qualitative inputs with documented clinical pathways and regulatory guidance to reduce the risk of anecdotal bias. The methodology prioritized transparency in assumptions and traceability of sources, and applied scenario-based reasoning to explore how policy shifts or technological advancements could alter implementation timelines and stakeholder incentives. Wherever possible, methodological rigor included explicit criteria for evaluating assay performance characteristics, evidence tiers required for clinical utility claims, and operational prerequisites for laboratory integration.

This structured approach yields insights that are rooted in practical clinicopathologic realities and are sensitive to the operational constraints of laboratories and health systems. It supports decision-making by linking technical performance attributes to clinical workflows and reimbursement dynamics, enabling stakeholders to design evidence strategies and implementation plans that align with real-world needs.

Synthesis of strategic priorities that connect analytic rigor, clinical integration, and operational resilience to maximize clinical and commercial impact

In conclusion, molecular oncology diagnostics sit at the intersection of technological possibility and clinical necessity. The path to meaningful impact demands more than incremental assay improvements; it requires integrated solutions that align analytic performance with clinician workflows, evidence strategies, supply chain resilience, and payer expectations. Organizations that embrace interoperable data platforms, modular evidence generation, and strategic partnerships with therapeutic developers will be best positioned to translate genomic insights into routine clinical decisions.

Operational resilience and market agility are equally essential, particularly in the face of policy-driven cost adjustments and supply chain pressures that can affect assay continuity and pricing dynamics. Tailoring commercial models to end-user realities, investing in health economic evidence, and prioritizing clinical utility in diverse patient populations are practical steps that will accelerate adoption and sustain long-term value. Ultimately, diagnostic providers that deliver clear, actionable, and reproducible results within clinician workflows will achieve the greatest clinical and commercial impact, strengthening oncology care and improving patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molecular Oncology Diagnostics Market, by Product Type

  • 8.1. Instruments
  • 8.2. Reagents & Kits
  • 8.3. Software & Services

9. Molecular Oncology Diagnostics Market, by Technology

  • 9.1. Fluorescence In Situ Hybridization
  • 9.2. Immunohistochemistry
  • 9.3. Microarray
  • 9.4. Next Generation Sequencing
    • 9.4.1. Targeted Sequencing
      • 9.4.1.1. Comprehensive Panel
      • 9.4.1.2. Hotspot Panel
    • 9.4.2. Whole Exome Sequencing
    • 9.4.3. Whole Genome Sequencing
  • 9.5. Real Time PCR

10. Molecular Oncology Diagnostics Market, by Cancer Type

  • 10.1. Breast Cancer
  • 10.2. Colorectal Cancer
  • 10.3. Leukemia
  • 10.4. Lung Cancer
  • 10.5. Prostate Cancer

11. Molecular Oncology Diagnostics Market, by Sample Type

  • 11.1. Plasma Based
  • 11.2. Saliva & Urine
  • 11.3. Tissue Based
  • 11.4. Whole Blood

12. Molecular Oncology Diagnostics Market, by Application

  • 12.1. Companion Diagnostics
  • 12.2. Early Detection
  • 12.3. Personalized Medicine
  • 12.4. Prognosis & Monitoring
  • 12.5. Research Use

13. Molecular Oncology Diagnostics Market, by End User

  • 13.1. Diagnostic Laboratories
  • 13.2. Hospitals & Clinics
  • 13.3. Pharmaceutical & Biotech Companies
  • 13.4. Research Institutes

14. Molecular Oncology Diagnostics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Molecular Oncology Diagnostics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Molecular Oncology Diagnostics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Molecular Oncology Diagnostics Market

18. China Molecular Oncology Diagnostics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Agilent Technologies, Inc.
  • 19.7. Bayer AG
  • 19.8. Becton, Dickinson and Company
  • 19.9. Bio-Rad Laboratories, Inc.
  • 19.10. Biocartis NV
  • 19.11. Biocept, Inc.
  • 19.12. BIOMERIEUX SA
  • 19.13. Danaher Corporation
  • 19.14. DiaSorin Molecular LLC
  • 19.15. Enzo Biochem, Inc.
  • 19.16. Exact Sciences Corporation
  • 19.17. F. Hoffmann-La Roche Ltd
  • 19.18. GenMark Saglik
  • 19.19. Guardant Health, Inc.
  • 19.20. Hologic, Inc.
  • 19.21. Illumina Inc.
  • 19.22. Leica Biosystems Nussloch GmbH
  • 19.23. Myriad Genetics, Inc.
  • 19.24. NeoGenomics Laboratories
  • 19.25. OncoCyte Corporation
  • 19.26. PathAI, Inc.
  • 19.27. Personal Genome Diagnostics Inc.
  • 19.28. QIAGEN N.V.
  • 19.29. Siemens AG
  • 19.30. Sysmex Asia Pacific Pte Ltd.
  • 19.31. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPREHENSIVE PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOTSPOT PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PLASMA BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SALIVA & URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TISSUE BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY EARLY DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROGNOSIS & MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 190. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 191. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 217. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 218. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 221. G7 MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 226. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 227. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 230. NATO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TARGETED SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)